DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Audino AN, Barth MJ, Tiwari A. et al.
Polatuzumab vedotin, an antibody-drug conjugate targeting CD79b, is a highly active agent against Burkitt lymphoma and primary mediastinal B-cell lymphoma.
Blood 2019;
134 (Supplement_1): 3963
Access:
We do not assume any responsibility for the contents of the web pages of other providers.